# Haynes Boone Advises Oramed Through Transformative Transaction with Lifeward

By Rick A. Werner, Simin Sun, Alla Digilova, Jennifer S. Kreick, Sam Lichtman, Jeffrey A. Wolfson, Cheyenne Karp, Brent Duddles, Lisa Vasek | January 13, 2026

RELATED PRACTICES Capital Markets and Securities, Corporate, Patent Prosecution and Counseling, Mergers and Acquisitions, Healthcare and Life Sciences, Tax

Haynes Boone represented Oramed Pharmaceuticals Inc., a clinical-stage pharmaceutical company pioneering oral drug delivery solutions, in its strategic transaction with Lifeward Ltd., a revenue-generating medical robotics company. This deal integrates pharmaceutical technology with advanced rehabilitation systems, positioning Oramed as a significant shareholder and creating a diversified platform for growth in life sciences and healthcare technology.

The transaction involves the transfer of Oramed's proprietary oral drug delivery POD™ technology to Lifeward, granting Oramed a 49.9 percent beneficial ownership interest in Lifeward, alongside warrants upon the satisfaction of certain terms and conditions. Oramed also agreed to invest in Lifeward through a $9 million senior secured convertible note and an additional milestone-based $9 million senior secured convertible note, each with 100 percent warrant coverage.

Haynes Boone Capital Markets and Securities Co-Chair Rick Werner, Mergers and Acquisitions Partner Simin Sun and Capital Markets and Securities Partner Alla Digilova led the team, with assistance from:

- Healthcare and Life Sciences Co-Chair Jennifer Kreick
- Business Planning and Tax Chair Sam Lichtman
- Patent Prosecution Chair Jeff Wolfson
- Corporate Associates Cheyenne Karp, Brent Duddles and Lisa Vasek

"We were delighted to support Oramed in executing this transformative transaction," said Werner. "Our group's deep experience in life sciences, healthcare technology and strategic investments allowed us to deliver a seamless process and help Oramed achieve its vision of combining oral drug delivery innovation with Lifeward's proven medical robotics business."

Haynes Boone's Capital Markets and Securities Practice advises on high-value public offerings, including IPOs, PIPEs, reverse mergers and dual listings. The team has led landmark deals across energy, tech, life sciences and financial services, including one of the largest IPOs in LSE history and the first Nasdaq-LSE dual listing of this century. Clients rely on our cross-border experience and integrated counsel across major U.S., U.K. and global exchanges for securities transactions, compliance and REIT structuring.

© 2026 Haynes and Boone, LLP